Effects of biomedical messages and expert-recommended messages on reducing mental health-related stigma: a randomised controlled trial.


Journal

Epidemiology and psychiatric sciences
ISSN: 2045-7979
Titre abrégé: Epidemiol Psychiatr Sci
Pays: England
ID NLM: 101561091

Informations de publication

Date de publication:
22 Nov 2019
Historique:
pubmed: 23 11 2019
medline: 27 5 2020
entrez: 23 11 2019
Statut: epublish

Résumé

Mental health-related stigma is a major challenge associated with the huge mental health treatment gap. It has remained unclear what kind of educational content is effective in reducing the stigma. Whether biomedical messages (BMM) about mental illness are effective or harmful in decreasing stigma is controversial. To investigate whether BMM can improve practically useful knowledge of mental illness, comparably to recommended messages (RCM) advocated by experts, of types such as 'recovery-oriented', 'social inclusion/human rights' and 'high prevalence of mental illnesses' through a randomised controlled trial (RCT). This study is an individual-level RCT with a parallel-group design over 1 year, conducted in Tokyo, Japan. A total of 179 participants (males n = 80, mean age = 21.9 years and s.d. = 7.8) were recruited in high schools and universities, and through a commercial internet advertisement in June and July 2017, without any indication that the study appertained to mental health. Participants were allocated to the BMM and RCM groups. They underwent a 10-min intervention, and completed self-report questionnaires during baseline, post-test, 1-month follow-up and 1-year follow-up surveys. The primary outcome measures were practically useful knowledge of mental illness at the post-test survey using the Mental Illness and Disorder Understanding Scale (MIDUS). Analysis was conducted in October 2018. Both groups demonstrated improved MIDUS score in the post-test survey, and showed similar intervention effects (F(1, 177) = 160.5, p < 0.001, η2 = 0.48). The effect of the interventions continued until the 1-year follow-up survey (B [95% CI] = -2.56 [-4.27, -0.85], p < 0.01), and showed no difference between groups. The reported adverse effect that BMM increase stigma was not confirmed. BMM may have a positive impact on stigma, comparable to RCM. These findings may encourage reconsideration of the content of messages about mental health, as it is indicated that combining BMM and RCM might contribute to an effective anti-stigma programme.

Identifiants

pubmed: 31753045
doi: 10.1017/S2045796019000714
pii: S2045796019000714
pmc: PMC8061129
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e74

Références

Br J Psychiatry Suppl. 2005 Aug;48:s116-9
pubmed: 16055800
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
Lancet. 2016 Mar 12;387(10023):1123-1132
pubmed: 26410341
Eur Psychiatry. 2005 Dec;20(8):529-39
pubmed: 16171984
Br J Psychiatry. 2017 Apr;210(4):261-268
pubmed: 28153928
J Nerv Ment Dis. 2013 Jun;201(6):490-503
pubmed: 23719324
Psychiatry Res. 2018 Mar;261:264-268
pubmed: 29329046
World Psychiatry. 2014 Jun;13(2):161-75
pubmed: 24890069
Br J Psychiatry. 2011 Nov;199(5):367-72
pubmed: 22045945
Soc Psychiatry Psychiatr Epidemiol. 2019 Jan;54(1):33-42
pubmed: 30315333
Can J Psychiatry. 2016 Mar;61(3):154-8
pubmed: 27254090
Epidemiol Psychiatr Sci. 2012 Mar;21(1):73-85
pubmed: 22670415
Bull World Health Organ. 2004 Nov;82(11):858-66
pubmed: 15640922
Community Ment Health J. 2016 Apr;52(3):262-71
pubmed: 26173403
Psychiatry Clin Neurosci. 2014 Sep;68(9):666-73
pubmed: 24521323
Nat Commun. 2018 Feb 21;9(1):588
pubmed: 29467362
Epidemiol Psychiatr Sci. 2018 Apr;27(2):199-208
pubmed: 27989255
Annu Rev Clin Psychol. 2019 May 7;15:555-577
pubmed: 30444641
World Psychiatry. 2002 Feb;1(1):16-20
pubmed: 16946807
Clin Psychol Rev. 2010 Dec;30(8):907-22
pubmed: 20674114
Br J Psychiatry. 2007 Mar;190:192-3
pubmed: 17329736
Aust N Z J Psychiatry. 2015 Aug;49(8):751-2
pubmed: 25922354
Psychiatry Clin Neurosci. 2013 Nov;67(7):471-82
pubmed: 24118217
Psychiatr Serv. 2011 Jun;62(6):675-8
pubmed: 21632739
Psychiatr Serv. 2012;63(5):496-9
pubmed: 22388477
J Am Acad Child Adolesc Psychiatry. 2016 May;55(5):383-391.e1
pubmed: 27126852
Epidemiol Psychiatr Sci. 2011 Sep;20(3):263-71
pubmed: 21922969
Neurosci Biobehav Rev. 2014 Oct;46 Pt 4:604-27
pubmed: 25236781
Psychiatry Clin Neurosci. 2011 Aug;65(5):405-15
pubmed: 21851449
J Health Soc Behav. 2003 Jun;44(2):162-79
pubmed: 12866388
Psychiatry Clin Neurosci. 2014 Jun;68(6):448-55
pubmed: 24920378
Schizophr Bull. 2004;30(3):563-72
pubmed: 15631245
BMC Psychiatry. 2014 Dec 31;14:379
pubmed: 25551789
Soc Psychiatry Psychiatr Epidemiol. 2015 Oct;50(10):1519-26
pubmed: 25947634
Psychol Med. 2017 Aug;47(11):1867-1879
pubmed: 28196549
Acta Psychiatr Scand. 2012 Jun;125(6):440-52
pubmed: 22242976
J Clin Invest. 2009 Apr;119(4):700-5
pubmed: 19339761
Epidemiol Psichiatr Soc. 2010 Jan-Mar;19(1):72-9
pubmed: 20486426
Early Interv Psychiatry. 2013 May;7(2):109-21
pubmed: 23343220

Auteurs

Yasutaka Ojio (Y)

Center for Evolutionary Cognitive Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan.
Department of Community Mental Health & Law, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8553, Japan.

Sosei Yamaguchi (S)

Department of Community Mental Health & Law, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8553, Japan.

Kazusa Ohta (K)

Center for Evolutionary Cognitive Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan.
Department of Neuropsychiatry, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

Shuntaro Ando (S)

Department of Neuropsychiatry, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

Shinsuke Koike (S)

Center for Evolutionary Cognitive Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan.
Institute for Diversity & Adaptation of Human Mind (UTIDAHM), The University of Tokyo 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan.
UTokyo Center for Integrative Science of Human Behavior (CiSHuB), 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH